Blogs

Blogs

ASCOconnection.org is a forum for the exchange of views on topical issues in the field of oncology. The views expressed in the blogs, comments, and forums belong to the authors. They do not necessarily reflect the views or positions of the American Society of Clinical Oncology. Please read the Commenting Guidelines.

No Results.

Many of the successful, FDA-approved drugs commonly used in cancer care were developed at small biotech or pharma companies—so what role do the "big fish" play?
Support for federal research funding for cancer is not about politics. It's about people. There is no one in our society—liberal, conservative, libertarian, or just don’t care—who isn’t touched in some way by cancer.
Believe it or not, the Medicare Access and CHIP Reauthorization Act of 2015 was passed more than 1 year ago, and program changes begin in less than six months, on Janurary 1, 2017.
Nurse-led patient navigation services are clearly valuable. A study being presented at #ASCO16 may provide enough evidence of a survival benefit to make these services reimbursable.
This is the story of how, like Mr. Smith in Washington, the medical community in Brazil gathered to speak truth to power about the lack of evidence for phosphoethanolamine as a cancer treatment.
ASCO commends the FDA for exercising its congressionally mandated authority to regulate cigars, hookah tobacco, electronic cigarettes (e-cigarettes), and other electronic nicotine delivery systems (ENDS), a crucial step in further regulating deadly tobacco products.
Whether you love or hate e-prescribing depends on whether you are writing, filling, or taking the pills.
This is the story of how a populist Congress approved the medication that wasn't, and oncologists in the country are waiting to see if an enfeebled president will be able to veto the bill.
This year’s report clearly shows that strengthening the delivery system for cancer care has to be pursued just as aggressively as its research agenda.
This is the story of how an eager chemistry professor and a well-intended but misguided federal judge transformed cancer care and drug development in Brazil into a convoluted soap opera.
The American Board of Internal Medicine (ABIM) invited all ABIM-certified physicians to participate in a review of the blueprints that outline content areas for subspecialty Maintenance of Certification (MOC) exams.
ASCO CEO Dr. Allen S. Lichter reflects on an optimistic approach to the challenges of providing high-quality cancer care around the globe on World Cancer Day.
The decision to scale up the provision of oral chemotherapy was a watershed event in the regulation of private health insurance in Brazil; however, prospects for expanded access to such medicines in the public health system are bleak in the short term.
In the face of limited health care resources and a rising national health budget, it is important to consider value when making treatment decisions for patients with cancer. This is a key question for all of us involved in cancer care and research. The answer may be a bit different coming from the...
Price discrimination is an inequitable-sounding, but important, concept of charging different prices for the same product or service in different markets or segments of a market, usually based on consumers’ ability to pay.
Participate in a Breakout Session on "Perspectives on Physician Aid in Dying" on Friday, January 22, at the 2016 Gastroinestinal Cancers Symposium, led by Chair Dr. George Fisher and speakers Dr. Lynne P Taylor and Dr. Kavitha Ramchandran.
ASCO staff and  member representatives gathered in Atlanta for the AMA House of Delegates' recent meeting, and, as usual, listened, learned, and spoke on a number of topics.
The Medicare Access and CHIP Reauthorization Act of 2015 (MACRA), which passed earlier this year, repealed the fundamentally flawed Sustainable Growth Rate formula and introduced significant changes in how Medicare will pay oncologists for the care they provide in the coming years.

Pages


Advertisement